PrEP can help anyone prevent HIV. Why do so few people take it?

Truvada,thepre-exposureprophylaxispillmanufacturedbyGilead.JustinSullivan/GettyImagesAbout60%ofolder AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs




leisure time

author：fashion    Page View：278
Alexis Borisy
Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

advertisement

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In
Previous article： 'Insanity': 4th of July mass shootings across US kill 13, injure more than 80
Next article： Virginia high school admissions case could be legal follow